Back to Research Library
Compound Profiles 15 min read

Growth Hormone Secretagogues

Understanding CJC-1295, Ipamorelin, and GHRP series in growth hormone axis research.

Introduction to the Growth Hormone Axis

The growth hormone (GH) axis is a sophisticated neuroendocrine network regulating metabolism, body composition, tissue regeneration, and a broad array of physiological functions. The core circuit involves:

  1. •Hypothalamus releases GHRH (Growth Hormone Releasing Hormone) and Somatostatin (the inhibitory counterpart)
  2. •Anterior pituitary responds by releasing GH in characteristic pulsatile bursts
  3. •Liver transduces the GH signal into IGF-1 (Insulin-like Growth Factor 1)
  4. •Peripheral tissues respond to both GH and IGF-1 directly

Growth Hormone Secretagogues (GHS) are peptides engineered or identified to stimulate or amplify GH output through various receptor-mediated mechanisms, making them subjects of sustained scientific investigation.

GHRH Analogues

CJC-1295

CJC-1295 is a laboratory-synthesised analogue of endogenous GHRH, structurally modified to significantly extend its biological half-life.

Mechanism: Binds GHRH receptors in the pituitary gland, driving GH secretion in a manner analogous to naturally occurring GHRH pulses.

Key structural modifications:

  • •Specific amino acid substitutions to prevent DPP-IV enzymatic cleavage
  • •DAC (Drug Affinity Complex) variant binds serum albumin, extending half-life to approximately 8 days
  • •Non-DAC form maintains a half-life of around 30 minutes, more closely replicating the natural GHRH pulse pattern

Research profile:

  • •Dose-dependent increase in circulating GH levels
  • •Elevation of IGF-1 concentrations
  • •Investigated for applications in fat metabolism, lean mass, and tissue recovery

Sermorelin

An earlier GHRH analogue encompassing the first 29 amino acids of endogenous GHRH. While its half-life is shorter than CJC-1295, sermorelin has an extensive record in clinical GH axis research and deficiency assessment.

Ghrelin Mimetics (GHRPs)

Ghrelin is the endogenous "hunger hormone" that also potently stimulates GH release via the GHSR-1a receptor. GHRPs are synthetic compounds that replicate this ghrelin-like activity.

Ipamorelin

Widely regarded as the most receptor-selective GHRP, ipamorelin is distinguished by its targeted pharmacological profile.

Mechanism: Selective GHSR-1a agonist — drives GH release without significant concurrent elevation of cortisol or prolactin.

Research advantages:

  • •High GH selectivity with minimal cortisol or prolactin effects at standard research amounts
  • •Does not produce pronounced desensitisation of GH axis receptors
  • •Well-characterised pharmacological profile across animal studies

Research findings:

  • •Dose-dependent GH release stimulation
  • •Synergistic effect observed when combined with GHRH analogues
  • •Animal studies demonstrate effects on bone density and adipose tissue

GHRP-2

A more potent GHRP compared to ipamorelin, but with a broader receptor profile:

  • •Stronger GH release stimulation in some experimental models
  • •Concurrent elevation of cortisol and prolactin at higher research quantities
  • •Appetite stimulation through ghrelin pathway engagement

GHRP-6

One of the earliest identified synthetic GHRPs, with an extensive published history:

  • •Pronounced appetite-stimulating activity
  • •Strong GH secretagogue effect
  • •Investigated in GH deficiency research models
  • •Gastric mucosal protective properties documented in some studies

CJC-1295 + Ipamorelin: A Combined Research Protocol

The pairing of a GHRH analogue with a GHRP has become a well-established research framework. The mechanistic rationale:

  • •GHRH analogues act directly on pituitary somatotrophs to increase GH pulse amplitude
  • •GHRPs engage GHSR-1a to initiate GH secretion and reduce somatostatin-mediated inhibition
  • •Together, they generate synergistic GH output substantially greater than either agent individually

Studies have reported up to 3–5x greater GH release with combined administration versus either compound alone, establishing this as a standard model in GH axis research.

Hexarelin

A potent hexapeptide GHRP with additional cardiovascular research relevance:

  • •High-affinity binding at GHS-R1a receptors
  • •Also interacts with the CD36 receptor — relevant to cardiac tissue research
  • •Cardioprotective effects have been observed in preclinical heart failure models independently of GH release

MK-677 (Ibutamoren)

Though not a peptide by classification (it is a small molecule), MK-677 is a non-peptide GHS frequently referenced alongside GHRP research:

  • •Oral bioavailability — does not require injection
  • •Extended half-life (~24 hours)
  • •Extensively investigated for its effects on the GH/IGF-1 axis, lean mass, and bone density

Research Design Considerations

Pulsatility and Timing

The GH axis is inherently pulsatile. Sound research protocols must account for:

  • •Natural GH pulse timing (predominantly nocturnal)
  • •Meal timing effects — GH secretion is dampened in hyperglycaemic states
  • •Pulse frequency and its relationship to receptor sensitivity

Somatostatin Tone

Somatostatin acts as the primary brake on GH release. GHRPs work in part by attenuating somatostatin tone. Studies examining this interaction should include somatostatin measurements where applicable.

IGF-1 as a Research Endpoint

IGF-1 provides an integrated, time-averaged index of GH axis activity and serves as a standard measurement endpoint in GH secretagogue studies.

Key Literature Venues

Significant research in this field has been published in:

  • •Growth Hormone & IGF Research
  • •Journal of Clinical Endocrinology & Metabolism
  • •European Journal of Endocrinology
  • •Endocrinology

This article is for research and educational purposes only. These compounds are not approved for human therapeutic use.

Research Use Only: All products are sold strictly for in-vitro laboratory research purposes. Not for human or veterinary consumption. Not approved by the MHRA for any therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease. Purchaser must be 18+ and a qualified researcher.

King Pharma

King Pharma is a UK-based supplier of independently verified, laboratory-grade peptide research compounds. All products are supplied for qualified scientific research use only.

⚠️ None of our products are intended for human use. No medicinal claims are made or implied.

© 2026 King Pharma Ltd. All rights reserved. Registered in England & Wales.

Secure payments:
VISAMCAMEXMaestro